TRYP:CC News and Press, Tryp Therapeutics Inc. From 07/08/22

TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT Canada NewsWire SAN DIEGO , July 8, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (" Tryp " or the " Company "), a clinical-stage biotechnology company foc...

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of a new provisional patent for the use of psilocybin for the treatment of patients with b...

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that Sid Taubenfeld, a seasoned executive with health care and biotech expertise, has joined the comp...

Tryp Therapeutics Appoints New Chief Operating Officer Canada NewsWire Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments SAN ...

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced the results gathered from the first patient dosed in its phase II STOP clinical trial. According to the...

TRYP THERAPEUTICS ANNOUNCES RESULTS OF FIRST PATIENT DOSED IN ITS PHASE II CLINICAL TRIAL FOR THE TREATMENT OF BINGE EATING DISORDER Canada NewsWire Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatme...

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive e...

Tryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent Director Canada NewsWire Industry leader Chris Ntoumenopoulos to support biotech Company's mission to advance the delivery of psychedelic medicines SAN DIEG...

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the first patient has been dosed in the company’s phase II clinical trial for its lead ca...

TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL Canada NewsWire Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder SAN DIEGO , ...